
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
0874.HKHKSEHealthcareMedical - Pharmaceuticals
Latest quote
HK$14.18
−HK$0.89 · -5.91%
0874.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials and their intermediates, alongside natural and biological remedies, serving both the Chinese domestic market and international clientele. The company's operations are strategically divided into four primary segments: Great Southern TCM, Great Commerce, Great Health, and Others. Beyond its manufacturing activities, GBPHCL is actively involved in the import, export, wholesale, and retail of both Western and Chinese medicines, as well as medical equipment. The company also develops, manufactures, and sells various consumer goods including beverages, food products, health supplements, pre-packaged foods, dairy items, and diverse pharmaceutical forms such as tablets, capsules, lozenges, and injections, in addition to traditional items like tortoise herb jelly. Furthermore, GBPHCL makes strategic investments in the broader health industry, covering areas like medical services, health management, wellness initiatives, and elderly care. It also provides commercial and advertising solutions. As of December 31, 2021, the company maintained a substantial retail presence, managing 154 chain pharmacies operating under brands like Cai Zhi Lin, Jian Min, GPC Prescription Pharmacy, and Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd, supplemented by an additional 22 independent retail stores. Established in 1997, the company originally operated as Guangzhou Pharmaceutical Company Limited before adopting its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. Its headquarters are situated in Guangzhou, China.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Hong Li
- Listed since
- Oct 30, 1997
- Employees
- 27,057
Market position
Day range
Current HK$14.18
52-week range
Current HK$14.18
- Open
- HK$14.78
- Previous close
- HK$15.07
- Volume
- 5.43M
- 5.4× average
- Average volume
- 1M
- Average daily volume
- Market cap
- 35.23B HKD
- Beta
- 0.18
- Market reference 1
- 50-day average
- HK$15.2982
- -7.31% below average
- 200-day average
- HK$17.3163
- -18.11% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 31.63B CNY
- P/E (TTM)
- 12.73×
- P/B (TTM)
- 0.73×
- P/S (TTM)
- 0.42×
- EV / EBITDA
- 8×
- Earnings yield
- 11.53%
- Free cash flow yield
- -3.69%
- Dividend yield
- 4.23%
Profitability & efficiency
- Gross margin
- 15.48%
- Operating margin
- 3.79%
- Net margin
- 3.24%
- Return on equity
- 7.89%
- Return on assets
- 3.53%
- Return on invested capital
- 4.81%
Financial health
- Debt / equity
- 0.47×
- Current ratio
- 1.57×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 77.66B CNY | 74.99B CNY | 75.52B CNY | 70.79B CNY | 69.01B CNY |
| Cost of goods sold | 65.05B CNY | 62.47B CNY | 61.33B CNY | 57.51B CNY | 55.78B CNY |
| Gross profit | 12.52B CNY | 12.52B CNY | 14.19B CNY | 13.28B CNY | 13.23B CNY |
| Research and development | 591.88M CNY | 763.77M CNY | 782.14M CNY | 819.45M CNY | 874.72M CNY |
| Selling, general, and administrative | 3.14B CNY | 3B CNY | 6.71B CNY | 6.43B CNY | 6.43B CNY |
| Operating expenses | 8.89B CNY | 8.92B CNY | 9.07B CNY | 8.73B CNY | 8.85B CNY |
| Interest income | 638.25M CNY | 404.31M CNY | 462.43M CNY | 626.79M CNY | 563.87M CNY |
| Interest expense | 415.95M CNY | 418.15M CNY | 446.19M CNY | 434.41M CNY | 417.83M CNY |
| Depreciation and amortization | 931.11M CNY | 875.24M CNY | 929.44M CNY | 743.83M CNY | 676.99M CNY |
| Operating income | 3.63B CNY | 3.6B CNY | 5.12B CNY | 5.07B CNY | 4.79B CNY |
| Net income | 2.98B CNY | 2.84B CNY | 4.06B CNY | 3.97B CNY | 3.72B CNY |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 44%
- 4 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -6.28%
- 9 comparable reports
- Latest EPS result
- 0.22
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.8761
2025 complete year+33.8% since 2021
2026 partial: HK$0.5162
HK$0.6547
2,021
HK$0.805
2,022
HK$0.8126
2,023
HK$1.2649
2,024
HK$0.8761
2,025
HK$0.5162
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 12, 2026 | HK$0.5162Semi-Annual | Jun 15, 2026 | Jul 17, 2026 |
Dividend | Aug 29, 2025 | HK$0.4399Semi-Annual | Sep 1, 2025 | Sep 26, 2025 |
Dividend | Jun 16, 2025 | HK$0.4362Semi-Annual | Jun 17, 2025 | Jul 18, 2025 |
Dividend | Oct 15, 2024 | HK$0.4422Semi-Annual | Oct 16, 2024 | Nov 15, 2024 |
Dividend | Jun 13, 2024 | HK$0.8227Semi-Annual | Jun 14, 2024 | Jul 18, 2024 |
Dividend | Jun 14, 2023 | HK$0.8126Annual | Jun 15, 2023 | Jul 17, 2023 |
Ex-dividend Jun 12, 2026
HK$0.5162
Semi-Annual
Record Jun 15, 2026 · Payment Jul 17, 2026
Ex-dividend Aug 29, 2025
HK$0.4399
Semi-Annual
Record Sep 1, 2025 · Payment Sep 26, 2025
Ex-dividend Jun 16, 2025
HK$0.4362
Semi-Annual
Record Jun 17, 2025 · Payment Jul 18, 2025
Ex-dividend Oct 15, 2024
HK$0.4422
Semi-Annual
Record Oct 16, 2024 · Payment Nov 15, 2024
Ex-dividend Jun 13, 2024
HK$0.8227
Semi-Annual
Record Jun 14, 2024 · Payment Jul 18, 2024
Ex-dividend Jun 14, 2023
HK$0.8126
Annual
Record Jun 15, 2023 · Payment Jul 17, 2023
0874.HK peers
Continue in GoAI
Research 0874.HKresearch.disclaimer





